Clinical trials: PCNSL
Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT03733327
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Primary CNS Lymphoma
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma.
- Trial name
- CAROUSEL (NCT04443829)
- Testing
- CD19CAR T-cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Lymphoma, Non-Hodgkin, HIV Infections
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide…
- Trial name
- NCT00000801
- Testing
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology.
- Trial name
- NCT07188077
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Primary Central Nervous System Lymphoma
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to…
- Trial name
- NCT05347641
- Testing
- Penpulimab
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma
Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00003261
- Testing
- methotrexate, zidovudine, neoadjuvant therapy
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Primary Central Nervous System Lymphoma
Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
This is a prospective multicenter single-arm phase II study, and the purpose of this study is to evaluate the efficiency of Orelabrutinib combined with PD-1 inhibitor regimen relapsed/refractory primary intraocular lymphoma.
- Trial name
- NCT04899427
- Testing
- orelabrutinib, Sintilimab, Tislelizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
Cancer
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation.
- Trial name
- NCT00008359
- Testing
- caspofungin acetate, liposomal amphotericin B
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a…
- Trial name
- NCT07523737
- Testing
- Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Beijing Tongren Hospital
Primary Central Nervous System Lymphoma (PCNSL)
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence).
- Trial name
- NCT04401774
- Testing
- Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT05931328
- Testing
- thiotepa combined with pomalidomide
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Central Nervous System Lymphoma
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma.
- Trial name
- NCT00293475
- Testing
- Carboplatin, Mannitol, Methotrexate
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- OHSU Knight Cancer Institute
Central Nervous System Lymphoma
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
The study will include 28 patients with primary CNS DLBCL who are ineligible with autologous hematopoietic stem cell transplantation or whole brain radiation therapy as consolidation therapy.
- Trial name
- PCNSL-LEM (NCT05260619)
- Testing
- lenalidomide
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Seoul National University Bundang Hospital
Brain and Nervous System, Eye and Orbit
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a tolerated dose (based on dose-limiting…
- Trial name
- NCT04022980
- Testing
- Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Lymphoma, Small Intestine Cancer
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with abnormal liver or kidney function or who have received…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003368
- Testing
- irinotecan hydrochloride
- Where
- 45 sites in United States
- Sponsor
- National Cancer Institute (NCI)
CNS Lymphoma
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
- Trial name
- CLIMB (NCT05828628)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated…
- Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
- Trial name
- STARLIGHT-1 (NCT06343311)
- Testing
- EB103
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Estrella Immunopharma, Inc.
Primary Central Nervous System Lymphoma, Recurrent Cancer
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).
- Conditions
- Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
- Trial name
- NCT04421560
- Testing
- Ibrutinib, Pembrolizumab, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
B-cell Lymphomas
High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse.
- Trial name
- SCNSL1 (NCT00801216)
- Testing
- High-dose sequential chemotherapy and autologous transplant
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Andrés José Maria Ferreri